Myriad Genetics

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myriad Genetics reports robust Q4 growth and eyes market expansion

Myriad Genetics showcased strong revenue growth and strategic initiatives to drive profitability in Q4 2022.
The company's focus on customer engagement, product volumes, and market positioning reflects a commitment to growth and operational excellence.
Challenges in managing competition and optimizing operational efficiency are balanced by opportunities for revenue growth and market expansion.

Myriad Genetics reports strong Q1 earnings, eyes profitability in Q4

Myriad Genetics demonstrated robust performance in Q1, leveraging strategic partnerships and operational improvements to drive revenue growth and enhance testing volumes.
While facing challenges like billing issues and seasonality-related declines, the company remains focused on core products, profitability, and growth opportunities.
With a strong financial outlook, emphasis on innovation, and commercial initiatives, Myriad Genetics is well-positioned to capitalize on market opportunities and drive sustainable growth.

Myriad Genetics reports solid Q2 growth and strategic focus

Myriad Genetics showcased strong financial performance, operational efficiencies, and strategic focus on growth and profitability.
While facing challenges like milestone payment concerns and industry competition, the company's strengths in key segments and operational capabilities position them well.
Opportunities in product enhancements, channel expansions, and investor engagement pave the way for continued success and market leadership.

Myriad Genetics reports strong Q3 earnings and raises 2024 guidance

Myriad Genetics reported strong revenue growth and operational improvements, with a focus on key product lines and enhancing customer experience.
The company raised financial guidance for 2023 and introduced revenue guidance for 2024, showcasing confidence in achieving long-term growth targets.
Challenges include regulatory changes, market penetration, and maintaining profitability amidst competitive dynamics, while opportunities lie in sustained growth and revenue optimization.
Overall, Myriad Genetics demonstrated resilience and strategic focus in driving growth, improving margins, and navigating market challenges effectively.

Myriad Genetics reports strong Q4 performance and eyes market expansion

Myriad Genetics delivered a strong Q4 performance with a focus on growth, strategic investments, and operational improvements. The company faces challenges in pricing and reimbursement but sees opportunities in market expansion and new product launches. Overall, Myriad Genetics is optimistic about its future prospects and market positioning.

Myriad Genetics reports robust Q1 performance and eyes growth opportunities

Myriad Genetics delivered a strong quarter with revenue growth and positive EBITDA, focusing on strategic areas like oncology and women's health. The company is optimistic about exceeding guidance but remains cautious. Analysts raised inquiries about various segments and operational decisions, with the company emphasizing profitable growth and maintaining margins.

Myriad Genetics reports strong Q2 performance and raises revenue targets

Myriad Genetics delivered a robust Q2 performance with revenue growth, positive earnings, and strategic wins in payer coverage, setting the stage for continued growth.
The company's focus on efficiency, customer satisfaction, and profitable growth positions it well for future success amidst market challenges and opportunities.
With raised revenue targets, expanded market acceptance, and operational excellence, Myriad Genetics demonstrates resilience and adaptability in a dynamic healthcare landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.

Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing

Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms

77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey

Intermountain Precision Genomics Laboratory receives certification from NYS Department of Health Clinical Laboratory Evaluation Program Intermountain Precision Genomics Laboratory receives certification from NYS Department of Health Clinical Laboratory Evaluation Program

Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification

Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.

Myriad Genetics' (MYGN) New Pact to Boost Precision Medicine

New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient care New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient care

Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program

Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.

Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access

Butterfly Network

Glenview Capital Management, the firm founded by Larry Robbins (Trades, Portfolio), disclosed in regulatory filings that it boosted during February its holdings in Myriad Genetics Inc. ( MYGN , Financial) and Butterfly Network Inc. ( BFLY , Financial) according to GuruFocus Real-Time Picks, a Premium feature.

Larry Robbins' Firm Boosts 2 Health Care Stocks

Illumina

Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry SAN DIEGO , March 2, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous recombination deficiency (HRD) testing in the United States. Under the agreement, Illumina TruSight™ Oncology 500 HRD (TSO 500 HRD), a research-use-only test, is now available in the US.

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.

Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls

SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the first evidence-based expanded carrier screening (ECS) practice guidelines for reproductive risk assessment published by the National Society of Genetic Counselors (NSGC) in the Journal of Genetic Counseling.

Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC

Myriad Genetics, Inc. (NASDAQ:MYGN ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Matthew Scalo - SVP, Investor Relations Paul Diaz - CEO, President & Director Nicole Lambert - COO Bryan Riggsbee - EVP, CFO & Treasurer Mark Verratti - Chief Commercial Officer. Conference Call Participants Tom Stevens - Cowen and Company Jack Meehan - Nephron Research Operator Greetings, and welcome to the Myriad Genetics Fourth Quarter 2022 Financial Earnings Conference Call.

Myriad Genetics, Inc. (MYGN) Q4 2022 Earnings Call Transcript

Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q4 Loss, Tops Revenue Estimates

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

SALT LAKE CITY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth-quarter earnings conference call on Tuesday, Feb. 28, 2023 at 4:30 p.m. ET. The company's quarterly earnings will be released the same day after the market closes.

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate at the upcoming healthcare conferences.

Myriad Genetics to Participate in Upcoming Healthcare Conferences

SALT LAKE CITY, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, highlighted impactful clinical studies from 2022 that underscore the company's commitment to making genetic testing more accessible and equitable for all patient populations. To advance precision medicine, Myriad is dedicated to ongoing research and has published evidence demonstrating technological and scientific innovation in the areas of mental health, oncology, and women's health.

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.

Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind

SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a recent guideline update by the American College of Medical Genetics and Genomics (ACMG), reaffirming the clinical value of non-invasive prenatal screening (NIPS) for a range of chromosomal abnormalities. Myriad is dedicated to advancing NIPS with best-in-class technology and important product launches.

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan (JPM) Healthcare Conference on Monday, Jan. 9, 2023 at 4:30 p.m. PST/7:30 p.m. EST.

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of five senior executives to help further strengthen the company's product roadmap and improve commercial execution.

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

Myriad's MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries Myriad's MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) --   Myriad Genetics, Inc ., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.

Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment

SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41st Annual National Society of Genetic Counselors (NSGC) meeting, Nov. 16-19 in Nashville, Tenn.

News for Myriad Genetics Stock (MYGN)